Emerging within the UK, retatrutide, a new peptide , is sparking considerable interest within the scientific community regarding its ability for body management . This dual GIP and GLP-1 agent agonist appears to provide a considerable improvement over established therapies, showing encouraging results in preliminary clinical studies . Researchers s